- Home
- VCNX vs IPDN Comparison
VCNX vs IPDN Comparison
Compare VCNX & IPDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VCNX
- IPDN
- Stock Information
- Founded
- VCNX 2001
- IPDN 2003
- Country
- VCNX United States
- IPDN United States
- Employees
- VCNX N/A
- IPDN N/A
- Industry
- VCNX Biotechnology: Pharmaceutical Preparations
- IPDN EDP Services
- Sector
- VCNX Health Care
- IPDN Technology
- Exchange
- VCNX Nasdaq
- IPDN Nasdaq
- Market Cap
- VCNX 10.5M
- IPDN 10.2M
- IPO Year
- VCNX N/A
- IPDN 2013
- Fundamental
- Price
- VCNX $1.41
- IPDN $0.48
- Analyst Decision
- VCNX
- IPDN
- Analyst Count
- VCNX 0
- IPDN 0
- Target Price
- VCNX N/A
- IPDN N/A
- AVG Volume (30 Days)
- VCNX 96.1K
- IPDN 43.8K
- Earning Date
- VCNX 11-14-2024
- IPDN 11-14-2024
- Dividend Yield
- VCNX N/A
- IPDN N/A
- EPS Growth
- VCNX N/A
- IPDN N/A
- EPS
- VCNX N/A
- IPDN N/A
- Revenue
- VCNX $388,000.00
- IPDN $7,005,632.00
- Revenue This Year
- VCNX N/A
- IPDN N/A
- Revenue Next Year
- VCNX N/A
- IPDN N/A
- P/E Ratio
- VCNX N/A
- IPDN N/A
- Revenue Growth
- VCNX N/A
- IPDN N/A
- 52 Week Low
- VCNX $1.25
- IPDN $0.42
- 52 Week High
- VCNX $13.02
- IPDN $3.01
- Technical
- Relative Strength Index (RSI)
- VCNX 27.23
- IPDN 29.41
- Support Level
- VCNX $3.34
- IPDN $0.48
- Resistance Level
- VCNX $4.35
- IPDN $0.62
- Average True Range (ATR)
- VCNX 0.45
- IPDN 0.06
- MACD
- VCNX -0.19
- IPDN -0.02
- Stochastic Oscillator
- VCNX 0.00
- IPDN 0.97
About VCNX Vaccinex Inc.
Vaccinex Inc is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The company's lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. The firm has also developed a proprietary drug discovery platform, ActivMAb.
About IPDN Professional Diversity Network Inc.
Professional Diversity Network Inc is engaged in providing access to networking, training, educational and employment services to its registered users. It has three operating segments: the Professional Diversity Network (PDN) segment, which includes online professional networking communities with career resources for diverse cultural groups and employers looking to hire members; and the National Association of Professional Women (NAPW) segment, which is a women-only professional networking organization, the RemoteMore segment. The company generates majority of its revenue from PDN Segment.